Advertisement


Dong Wook Shin, MD, DrPH, MBA, on Thyroid Cancer: Risk of Side Effects

2017 Cancer Survivorship Symposium

Advertisement

Dong Wook Shin, MD, DrPH, MBA, of Seoul National University Cancer Hospital, discusses the risk of coronary heart disease and ischemic stroke in patients with thyroid cancer taking levothyroxine (Abstract 105).



Related Videos

Breast Cancer
Survivorship

Lauren P. Wallner, PhD, MPH, on Breast Cancer Survivorship Care: Patient Preferences

Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings on the type of providers women prefer when it comes to handling survivorship care after breast cancer treatment and the need to clarify and discuss provider roles with patients (Abstract 99).

Survivorship

K. Holly Mead, PhD, on Identifying Models of Cancer Survivorship Care

K. Holly Mead, PhD, of George Washington University, discusses specialized survivorship-specific programs, which are gaining prominence, with over 40% of cancer centers in her study providing this type of care (Abstract 1).

Survivorship

Ann H. Partridge, MD, MPH, on Adolescent and Young Adult Patients: Their Survivorship Challenges

Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute, summarizes a session she co-chaired on the unique issues affecting adolescent and young adult patients, including their psychosocial needs and concerns that clinicians may overlook.

Breast Cancer
Survivorship

Shoshana M. Rosenberg, ScD, MPH, on Young Breast Cancer Survivors: Helping Them Cope

Shoshana M. Rosenberg, ScD, MPH, of the Dana-Farber Cancer Institute, talks about ways to help young women move from active treatment to survivorship, based on findings from focus groups in which patients discussed their unexpected physical and psychological experiences after surgery (Abstract 180).

Survivorship

Emily S. Tonorezos, MD, on Childhood Cancer Survivors and Late-Occurring Effects

Emily S. Tonorezos, MD, of Memorial Sloan Kettering Cancer Center, discusses childhood cancer survivors and the protection from late-occurring anthracycline-related cardiotoxicity conferred by a RARG coding variant.

Advertisement

Advertisement




Advertisement